These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 26976796)

  • 1. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
    Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
    Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coffee Bioactive
    Quarta S; Scoditti E; Carluccio MA; Calabriso N; Santarpino G; Damiano F; Siculella L; Wabitsch M; Verri T; Favari C; Del Rio D; Mena P; De Caterina R; Massaro M
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
    Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
    Boujon V; Uhlemann R; Wegner S; Wright MB; Laufs U; Endres M; Kronenberg G; Gertz K
    J Mol Med (Berl); 2019 Aug; 97(8):1127-1138. PubMed ID: 31147725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
    Dietz M; Mohr P; Kuhn B; Maerki HP; Hartman P; Ruf A; Benz J; Grether U; Wright MB
    ChemMedChem; 2012 Jun; 7(6):1101-11. PubMed ID: 22489042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B
    IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.
    Hu X; Feng Y; Liu X; Zhao XF; Yu JH; Yang YS; Sydow-Bäckman M; Hörling J; Zierath JR; Leng Y
    Diabetologia; 2007 May; 50(5):1048-57. PubMed ID: 17333104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
    Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
    Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
    Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
    PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes.
    Chuang CC; Martinez K; Xie G; Kennedy A; Bumrungpert A; Overman A; Jia W; McIntosh MK
    Am J Clin Nutr; 2010 Dec; 92(6):1511-21. PubMed ID: 20943792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dietary Isoflavone Daidzein Reduces Expression of Pro-Inflammatory Genes through PPARα/γ and JNK Pathways in Adipocyte and Macrophage Co-Cultures.
    Sakamoto Y; Kanatsu J; Toh M; Naka A; Kondo K; Iida K
    PLoS One; 2016; 11(2):e0149676. PubMed ID: 26901838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γ-Tocotrienol attenuates TNF-α-induced changes in secretion and gene expression of MCP-1, IL-6 and adiponectin in 3T3-L1 adipocytes.
    Matsunaga T; Shoji A; Gu N; Joo E; Li S; Adachi T; Yamazaki H; Yasuda K; Kondoh T; Tsuda K
    Mol Med Rep; 2012 Apr; 5(4):905-9. PubMed ID: 22293775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.